In this study, we examine the relationship between HER2 expression and tumor heterogeneity with PTX treatment efficacy in controlled xenografted human breast cancer models: BT474 (high HER2+), MDA-MB-361 (low HER2+), MDA-MB-231 (HER2−) tumors with molecular imaging. This evidence concerns the gene ERBB2 and breast carcinoma.